3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase EARLY_PHASE1
1
Phase 1
1
Status
Recruiting
2
Terminated
1
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Dermatologic
2
Thoracic
1
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Melanoma
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Esophageal Neoplasms
1
Desmoid Tumors
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
1254
Specimen Handling
869
Carboplatin
818
Magnetic Resonance Spectroscopy
804
Cyclophosphamide
795
Cisplatin
716
Nivolumab
648
Paclitaxel
623
Radiotherapy
567
Gemcitabine
565
Biopsy
529
Bevacizumab
468
Dexamethasone
434
fludarabine
404
Docetaxel
373
venetoclax
366
Oxaliplatin
362
Capecitabine
353
Fluorouracil
352
atezolizumab
341
Rituximab
327
durvalumab
326
Doxorubicin
313
Radiosurgery
306
Pemetrexed
303
Drug Therapy
295
Standard of Care
292
Ipilimumab
290
Etoposide
280
Radiation
278
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Interventional
×
High-Intensity Focused Ultrasound Ablation
×
1 year
×
Clear all
NCT05111964
2026-02-04
SarcAblate
Oxford University Hospitals NHS Trust
Phase NA
Recruiting
10 enrolled
NCT06472661
2025-11-20
Mel 70
University of Virginia
Phase EARLY_PHASE1
Recruiting
11 enrolled
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled